11 January 2024
The agreement, announced this week by Portuguese biotech company CellmAbs, a spin-off of NOVA University Lisbon, includes patented technology originating from NOVA's Faculty of Science and Technology (NOVA FCT) and developed in collaboration with the Portuguese Institute of Oncology of Porto (IPO) and the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) in Germany.